Media OutReach
Hong Kong’s First PIC/S GMP-Certified Stem Cell Production Facility Established at Science Park
HKSTP Hosts Showcase Featuring Clinical Progress from 10 Park Companies and Real-Life Patient Stories
HONG KONG SAR – Media OutReach Newswire – 31 July 2026 – Hong Kong Science and Technology Parks Corporation (HKSTP) today hosted the HKSTP Cell and Gene Therapy (CGT) Showcase 2026 at the Charles K. Kao Auditorium, Hong Kong Science Park, with support from Invest Hong Kong. The event brought together more than 200 representatives from the healthcare, academic, investment and regulatory sectors, both locally and from overseas. A major milestone announced at the event was that HKSTP partner company Hong Kong Regen Medtech Limited (HKRM) has become the first facility in Hong Kong to be recognised by the Pharmacy and Poisons Board of Hong Kong (PPBHK) as an allogeneic mesenchymal stem cell (MSC) PIC/S GMP manufacturing facility, enabling the production of advanced therapy products for clinical trials.
Mr Terry Wong, CEO of HKSTP, said in his remarks: “Cell and gene therapy is one of the fastest-growing fields in life and health tech. The establishment of Hong Kong’s first stem cell production facility certified to PIC/S GMP standards at Hong Kong Science Park marks a significant milestone for the city’s life and health tech ecosystem. The significance of this certification goes far beyond technology alone. It signifies not only that production has met the highest international safety standards, but also that patients and their families can choose locally manufactured cell therapy products with confidence and complete trust. This is a tangible achievement that will enable every Hong Kong citizen to benefit directly. As the orchestrator of Hong Kong’s innovation and technology (I&T) ecosystem, HKSTP has been proactively connecting the life and health tech community with partners, investors and academia. Through a diverse range of incubation programmes, we provide our park companies with seed funding, innovation space, world-class infrastructure and regulatory support, helping them overcome challenges in the journey from laboratory research to clinical translation and turning scientific breakthroughs into real therapeutic outcomes for patients. We will continue to drive ecosystem development and fully support local I&T enterprises in bringing research achievements ‘Made in Hong Kong’ to the global stage.”
Hong Kong’s First PIC/S GMP Stem Cell Production Facility Bridges a Critical Gap from Research to Clinical Application
One of the highlights of the event was HKRM, an HKSTP partner company, recently obtaining Hong Kong’s first PIC/S GMP licence for stem cell production and operating the related manufacturing facility at Hong Kong Science Park, marking a key step in advancing the clinical translation of advanced therapies in Hong Kong. PIC/S GMP is internationally recognised as the gold standard for pharmaceutical manufacturing quality. Facilities must undergo rigorous international assessment to ensure that every batch is produced in a strictly controlled environment.
Mr Stanley Sy, HKRM Co-founder and CEO, said: “HKRM’s attainment of Hong Kong’s first PIC/S GMP certification for stem cell production marks not only an important milestone in the company’s development, but also signifies that Hong Kong now has the critical infrastructure needed to further support the clinical translation of advanced cell therapies. A stringent, internationally recognised manufacturing quality system helps ensure product consistency and traceability, while strengthening the confidence of medical and regulatory authorities in locally manufactured cell-based products. Based at Hong Kong Science Park, HKRM is grateful for the longstanding support of HKSTP. We also look forward to working with research and clinical partners in the Park to bring more promising therapeutic solutions from Hong Kong to the international stage.”
Patients, Families and Doctors Share First-hand Stories of the Journey from Cell Banking to Clinical Breakthroughs
The event also featured first-hand experiences from patients, their families and doctors on their treatment journeys. Park company Mononuclear Therapeutics (MonoTx) operates Hong Kong’s first AABB-accredited public cord blood bank and haematopoietic stem cell apheresis facility at Hong Kong Science Park, with more than 2,000 cord blood units in storage.
Dr Wendy Cheng, Chief Operating Officer of MonoTx, joined Professor Leung Tak Yeung and Professor Ronald Wang of the Department of Obstetrics and Gynaecology at The Chinese University of Hong Kong (CUHK) to share research findings and patient cases with patient families.
Professor Leung Tak Yeung’s team at CUHK is studying a treatment for foetuses with severe alpha-thalassaemia by processing the mother’s stem cells through MonoTx and infusing them into the foetus, to investigate whether the foetus can develop immune tolerance to the mother’s stem cells and thereby improve clinical outcomes.
Professor Ronald Wang’s team is using cord blood to treat neonatal brain injury. Preliminary findings suggest that cord blood infusion within 48 hours of birth may help repair brain injury and improve the child’s developmental outcomes later in life.
360 Life Sciences Companies Gather at Hong Kong Science Park, Reinforcing Hong Kong’s Position as an International Health and Medical Innovation Hub
Hong Kong Science Park is home to more than 360 life sciences companies, while the number of cell and gene therapy (CGT) enterprises continues to grow, spanning frontier fields such as stem cells, gene editing, personalised cancer vaccines and CAR-T immunotherapy, and addressing diseases including cancer, heart failure and neurodegenerative disorders. HKSTP will continue to strengthen Hong Kong’s position as an international health and medical innovation hub by accelerating the translation and application of more locally developed R&D outcomes for the benefit of patients, the industry and society. In doing so, it aims to make innovative therapies more accessible and enable Hong Kong to play an even greater role on the global life and health tech stage.
Hashtag: #HKSTP
The issuer is solely responsible for the content of this announcement.
Hong Kong Science and Technology Parks Corporation
Hong Kong Science and Technology Parks Corporation (HKSTP) was established in 2001 to create a thriving I&T ecosystem grooming 14 unicorns, more than 17,000 research professionals and over 2,400 technology companies from 26 countries and regions focused on developing healthtech, AI and robotics, fintech and smart city technologies, etc.
Our growing innovation ecosystem offers comprehensive support to attract and nurture talent, accelerate and commercialise innovation for technology ventures, with the I&T journey built around our key locations of Hong Kong Science Park in Pak Shek Kok, InnoCentre in Kowloon Tong and three modern InnoParks in Tai Po, Tseung Kwan O and Yuen Long realising a vision of new industrialisation for Hong Kong, where sectors including advanced manufacturing, micro-electronics and biotechnology are being reimagined.
Hong Kong Science Park Shenzhen Branch in Futian, Shenzhen plays positive roles in connecting the world and the mainland with our proximity, strengthening cross-border exchange to bring advantages in attracting global talent and allowing possibilities for the development of technology companies in seven key areas: Medtech, big data and AI, robotics, new materials, microelectronics, fintech and sustainability, with both dry and wet laboratories, co-working space, conference and exhibition facilities, and more.
Through our R&D infrastructure, startup support and enterprise services, commercialisation and investment expertise, partnership networks and talent traction, HKSTP continues to contribute in establishing I&T as a pillar of growth for Hong Kong.
More information about HKSTP is available at 
www.hkstp.org.
Media OutReach
APSIC and Schuelke Launch Asia Pacific Environment Hygiene Excellence Award to Elevate Hospital Infection Prevention Standards
New regional programme will assess environmental hygiene practices, support hospital improvement, and recognise excellence in patient safety across Asia Pacific, with winners honoured at the APSIC 2028 Congress.
SINGAPORE – Media OutReach Newswire – 31 July 2026 – The Asia Pacific Society of Infection Control (APSIC), in collaboration with Schuelke, has launched the APSIC Environment Hygiene Excellence Award, a programme to recognise hospitals that demonstrate excellence in environmental hygiene and infection prevention across the Asia Pacific region. The programme was announced today at the APSIC 2026 Congress.
Environmental hygiene is a critical component of infection prevention and patient safety, yet standards and implementation of environmental hygiene vary significantly across the region’s healthcare settings. The new programme aims to raise awareness, strengthen best practices, and support hospitals to improve environmental hygiene through a structured, scientifically guided framework.
Participating hospitals will be evaluated using APSIC-developed guidelines and audit criteria, with assessments conducted through an independent scientific framework led by an APSIC-appointed expert panel comprising infection prevention specialists from across the region.
“Environmental hygiene is fundamental to infection prevention and patient safety, yet often under-recognised. This initiative brings renewed focus to raising standards across healthcare systems in Asia Pacific,” said Professor Moi Lin Ling, APSIC Programme Chair, APSIC Environment Hygiene Excellence Award
Through this regional collaboration, APSIC and Schuelke aim to:
- Promote awareness and adoption of best practices in environmental hygiene across healthcare institutions in Asia Pacific.
- Provide hospitals with structured tools to assess performance and identify opportunities for improvement.
- Enable benchmarking and knowledge exchange among healthcare institutions to advance infection prevention standards regionally.
Shortlisted hospitals will receive expert-led educational support, including regional webinars and on-site training sessions, to help strengthen infection prevention strategies and improve operational environmental hygiene practices. Finalists will undergo an on-site audit by APSIC experts, and winners will be honoured at the APSIC 2028 Congress.
“As a long-standing partner in infection prevention, Schuelke is committed to supporting healthcare institutions in advancing environmental hygiene standards through scientific collaboration and education,” said Patrick Kaminski, President and CEO, Schuelke Asia Pacific.
The programme represents one of the first coordinated regional efforts to standardise, assess, and recognise excellence in environmental hygiene across healthcare systems in Asia Pacific. By combining scientific criteria, expert review, and practical education, the initiative is designed to support meaningful and measurable improvements in hospital hygiene, patient safety, and infection prevention outcomes.
Healthcare institutions interested in participating in the programme can find more information at www.ehea.health
Hashtag: #Schuelke
The issuer is solely responsible for the content of this announcement.
About Asia Pacific Society of Infection Control (APSIC)
APSIC was established in 1998 and is a multinational, voluntary organisation dedicated to advancing infection prevention and control practices to reduce hospital-associated infections, respond to emerging and re-emerging infectious diseases, and improve patient outcomes. APSIC brings together multidisciplinary infection prevention and control professionals across the region to share knowledge, experience, quality improvement initiatives, and research findings through training courses, seminars, congresses, and conferences in Asia Pacific. APSIC also works to establish collaborative partnerships that promote cost-effective, evidence-based practices across the region.
Learn more about APSIC at: 
https://apsic-apac.org/
About Schuelke
Schuelke, headquartered in Norderstedt, Germany, is a global leader in infection prevention and control with more than 135 years of experience. Guided by its purpose, “We protect lives worldwide,” Schuelke is committed to advancing health and safety through innovative solutions, scientific expertise, and strong partnerships across the healthcare ecosystem.
In an increasingly interconnected world where infectious risks transcend borders, Schuelke works closely with healthcare professionals, institutions, and industry partners to strengthen infection prevention practices across diverse care settings.
The company operates across four key business areas—Healthcare, Consumer Health (OTC), Direct Patient Care, and Life Sciences—offering a comprehensive portfolio of solutions spanning antisepsis, disinfection, hygiene management, and specialised applications.
With globally recognised brands such as mikrozid®, microshield®, octenisept®, desmanol®, and desderman®, Schuelke provides trusted solutions for surface disinfection, skin antisepsis, hand hygiene, and wound care, supporting healthcare professionals in maintaining safe and effective clinical environments.
Learn more about Schuelke at: https://www.schuelke.com
Media OutReach
AECOM opens new Hong Kong office and Asia headquarters, bringing together people, technology and sustainability
Designed as a living demonstration of the way AECOM works, the office brings together people, technology and sustainable design in a future-ready environment that reflects both the company’s values and its deep connection to Hong Kong.
The new workplace underlines the company’s commitment to Hong Kong. At a time of transformational development in Hong Kong, including landmark initiatives such as the Northern Metropolis and SKYTOPIA, it strengthens AECOM’s ability to support clients locally while leveraging its breadth of expertise across Asia.
Ian Chung, chief executive of AECOM’s Asia region, said: “Our new Hong Kong office and Asia headquarters represents AECOM’s largest office investment in Asia and reflects our confidence in Hong Kong’s future. For more than 50 years, we have partnered with clients and communities to help shape the city’s development. This new workplace will strengthen collaboration and innovation across our teams, enabling us to support the opportunities ahead and continue growing future Hong Kong together with our clients and partners.”
Johnny Cheuk, executive leader, Hong Kong, AECOM, said: “As Hong Kong enters a new era of development, creating the right environment for our people and clients to collaborate has never been more important. Our new office is designed to foster innovation, collaboration and multidisciplinary teamwork, strengthening our ability to deliver better outcomes for clients and communities. This future-ready workplace will help us bring together the talent and expertise needed to shape Hong Kong’s next chapter of growth.”
Occupying approximately 126,000 gross square feet across four floors, the workplace is designed around AECOM’s Freedom to Grow framework, supporting flexible, performance-led ways of working through a variety of spaces for focused work, project delivery, hybrid meetings and collaboration. Client engagement areas, innovation spaces and technology-enabled environments further support co-creation and knowledge sharing. It demonstrates the same people-centered and future-ready principles that AECOM helps clients deliver every day.
A digital dashboard powered by IoT sensors provides real-time insights into energy consumption and indoor air quality, making workplace sustainability performance visible and measurable. The relocation also embraced circular economy principles. More than 900 furniture items from AECOM’s previous Sha Tin office were donated to local schools and non-governmental organizations, extending their useful life while reducing landfill waste.
Employee wellbeing was integral to the design. Activity-based workspace design promotes the exchange of ideas, collaboration, socialization and focused work, while natural materials, green walls and planted dividers bring biophilic elements into the workplace. Bamboo finishes and sustainable carpets help reduce the environmental impact of the fit-out.
The workplace also reflects AECOM’s multidisciplinary strength in infrastructure delivery. The office is located at 83 King Lam Street, a twin-tower commercial development for which AECOM provided structural, geotechnical and façade engineering services. The project was recognized at the HKIE Structural Division Structural Excellence Award 2025.
Download more high-resolution images here.
Hashtag: #AECOMHongKong #AECOMHKNewOffice #GrowingFutureHKTogether #DeliveringABetterWorld
The issuer is solely responsible for the content of this announcement.
About AECOM
AECOM is the global infrastructure leader, committed to delivering a better world. As a trusted professional services firm powered by deep technical abilities, we solve our clients’ complex challenges in water, environment, energy, transportation and buildings. Our teams partner with public- and private-sector clients to create innovative, sustainable and resilient solutions throughout the project lifecycle — from advisory, planning, design and engineering to program and construction management. AECOM is a Fortune 500 firm that had revenue of US$16.1 billion in fiscal year 2025. Learn more at aecom.com.
The annual ranking, produced in collaboration with Statista, the world-leading statistics portal and industry ranking provider, recognises the most innovative and high-impact fintech firms globally.
“This recognition reflects the dedication of our team and the trust our customers and partners place in us every day,” said Bill Deng, Founder and CEO of XTransfer. “Cross-border financial operations can be complex, especially for SMEs. We focus on solving the real operational challenges behind international payments, reducing friction, improving visibility, and strengthening risk controls, so businesses can concentrate on growth.”
XTransfer‘s inclusion underscores the company’s growing role in the global payments ecosystem and its long-term mission to make cross-border trade payments simpler, safer, and more accessible for SMEs worldwide. XTransfer will continue to invest in compliance and product innovation, while deepening collaboration with top-tier financial institutions to help more businesses trade globally with confidence.
CNBC’s World’s Top Fintech Companies list evaluates thousands of firms across seven key segments, including Payments, Digital Assets, and Enterprise Technology. Companies were assessed based on quantitative KPIs, growth metrics, and industry influence, with data sourced from public reports, company submissions, and independent research.
Based on the results of the study, XTransfer is honoured to be recognised on CNBC’s World’s Top Fintech Companies 2026 list. View list here.
Hashtag: #XTransfer #CNBC #Crossborder #Payment #SMEs
https://www.xtransfer.com
https://www.linkedin.com/company/xtransfer.cn
https://x.com/xtransferglobal
The issuer is solely responsible for the content of this announcement.
XTransfer
XTransfer, the world’s largest B2B cross-border trade payment platform with over US$60 billion TPV in 2025, according to CIC. Founded in 2017 as one of the first payment platforms worldwide dedicated to B2B cross-border trade, we serve the largest customer base of over 890,000 registered SMEs globally.
We connect top-tier financial institutions directly to SMEs, the backbone of global trade, giving businesses of every size access to the same secure, compliant and seamless payment infrastructure once reserved for multinationals. As of March 31, 2026, we provide payment services across more than 200 countries and regions through partnerships with financial institutions, including some of the most established international banks around the world.
